Navigation Links
Vion Reports 2008 First Quarter Results
Date:5/5/2008

e quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007. In parti
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. eResearchTechnology Reports First Quarter 2008 Results
2. MannKind Corporation Reports First Quarter Financial Results
3. Verenium Reports Financial Results for the First Quarter 2008
4. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
5. United Therapeutics Reports First Quarter 2008 Financial Results
6. Endocare Reports 2008 First Quarter Financial Results
7. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
8. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Alexion Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... University researchers are finding ways to improve infrared photodetector ... systems, as well as used increasingly in commercial applications ... in a recent article in the journal ... how infrared photodetection can be done more effectively by ...
... LEXINGTON, Mass., Feb. 14, 2012 Avaxia Biologics, ... drugs that act locally within the gastrointestinal tract, ... million Series A angel-led financing.  Cherrystone Angels of ... from Beacon Angels, Boston Harbor Angels, Launchpad Venture ...
... PROVIDENCE, R.I., Feb. 14, 2012  Nabsys, Inc., a ... positional sequencing technology, today announced that data demonstrating ... DNA will be presented at the annual Advances ... 15 to 18, on Marco Island, Fla., and ...
Cached Biology Technology:New nano-material combinations produce leap in infrared technology 2New nano-material combinations produce leap in infrared technology 3Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 3Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Restoration International (SER) released its May 2008 Briefing ... & Biological Conservation within the Ecosystem Approach at ... the Parties held in Bonn, Germany, May 19-30, ... Ecosystem Approach, as developed by the CBD and ...
... and Technology (NIST) have reported* a new technique to ... centrifuges. Many potential applications for carbon nanotubes depend on ... the most important features of the new technique, say ... to produce industrial quantities of high-quality nanotubes. ...
... of shipments involving regulated radioactive materials used in medicine ... industry experts. Meeting in Rome this week at an ... the Mediterranean region that seeks to ease hardships for ... delivery of beneficial radiation sources. The shipment issues ...
Cached Biology News:Integrating restoration and conservation within the ecosystem approach 2Spin control: New technique sorts nanotubes by length 2Experts tackle shipment issues for beneficial radiation sources 2Experts tackle shipment issues for beneficial radiation sources 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Biology Products: